← 홈

CD19

218개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 218개
ADCBiologicstaleSeagen Inc.Phase 1

SGN-CD19A (SGN-CD19A)

Burkitt Lymphoma; Precursor B-cell Lymphoblastic Leukemia-Lymphoma · CD19

#CD19#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+3
임상시험 4상태 ACTIVE
CGTBiologicThe First Affiliated Hospital o…Preclinical

Anti-BCMA and CD19 CART cells will be injected intravenously on a one-time basis. (Anti-BCMA and CD19 CART cells will be injected intravenously on a one-time basis.)

Autoimmune Diseases · CD19

#CD19#CGT#Preclinical#세포유전치료#CAR-T+3
임상시험 3상태 RECRUITING
CGTBiologicstaleJuno Therapeutics, Inc., a Bris…Phase 2

Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes (Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes)

CD19-Positive Neoplastic Cells Present; Recurrent Adult Acute Lymphoblastic Leukemia · EGFR

#EGFR#CGT#Phase2#세포유전치료#CAR-T+4
효능 ORR 32%임상시험 3상태 ACTIVE
CGTBiologicstaleFondazione Matilde Tettamanti M…Phase 2

CARCIK-CD19 (CARCIK-CD19)

B-cell NHL; CLL · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 3상태 RECRUITING
CGTBiologicstaleKecellitics Biotech Company LtdPhase 2

CD19 and CD22 targeted CAR-T cells (CD19 and CD22 targeted CAR-T cells)

Lymphoma, B-Cell · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+4
효능 ORR 1%임상시험 3상태 ACTIVE
CGTBiologicstaleInnovative Cellular Therapeutic…Preclinical

CD19CART (CD19CART)

Leukemia, B-Cell; Lymphoma, B-Cell · CD19

#CD19#CGT#Preclinical#세포유전치료#CAR-T+5
임상시험 3상태 ACTIVE
CGTBiologicstaleUniversity of Colorado, DenverPhase 1

UCD19 CAR T Cells (UCD19 CAR T Cells)

Non Hodgkin Lymphoma · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 3상태 ACTIVE
CGTBiologicSecond Affiliated Hospital, Sch…Preclinical

Anti-CD19 IL-10/IL15 CAR-NK (Anti-CD19 IL-10/IL15 CAR-NK)

Systemic Sclerosis (SSc); ANCA Associated Vasculitis (AAV) · CD19

#CD19#CGT#Preclinical#세포유전치료#CAR-T+4
임상시험 2상태 RECRUITING
CGTBiologicstale920th Hospital of Joint Logisti…Phase 2

Anti-CD19 UCAR-NK cells (Anti-CD19 UCAR-NK cells)

B-Cell Lymphoblastic Leukemia/Lymphoma · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 2상태 DISCONTINUED
CGTBiologicstaleAnhui Provincial HospitalPreclinical

Anti-CD19/BCMA CAR gene vector injection will be injected intravenously on a one-time basis. (Anti-CD19/BCMA CAR gene vector injection will be injected intravenously on a one-time basis.)

Immune Thrombocytopenia (ITP) · CD19

#CD19#CGT#Preclinical#세포유전치료#CAR-T+3
임상시험 2상태 RECRUITING
CGTBiologicstaleYake Biotechnology Ltd.Phase 1

Assigned Interventions CD19/BCMA CAR T-cells (Assigned Interventions CD19/BCMA CAR T-cells)

Scleroderma; Autoimmune Diseases · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 2상태 ACTIVE
CGTBiologicstaleHebei Senlang Biotechnology Inc…Phase 2

Autologous CD19/CD22 Chimeric Antigen Receptor T-cells (Autologous CD19/CD22 Chimeric Antigen Receptor T-cells)

CD19 Positive; CD22 Positive · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 2상태 DISCONTINUED
CGTBiologicstaleJuno Therapeutics, Inc., a Bris…Phase 1

Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes (Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes)

Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent B-Cell Non-Hodgkin Lymphoma · EGFR

#EGFR#CGT#Phase1#세포유전치료#CAR-T+4
효능 ORR 1%임상시험 2상태 DISCONTINUED
CGTBiologicstaleAutolus LimitedPhase 2

CAR-T cells targeting CD19 and CD22 (CAR-T cells targeting CD19 and CD22)

B-Cell Acute Lymphoblastic Leukemia, Adult · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+4
효능 ORR 1%임상시험 2상태 RECRUITING
CGTBiologicstaleAthenex, Inc.Phase 1

CD19 CAR T-cell (CD19 CAR T-cell)

Membranous Nephropathy; Lupus Nephritis (LN) · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+4
효능 ORR 67%임상시험 2상태 RECRUITING
CGTBiologicstaleTimmune Biotech Inc.Phase 1

CD19-TriCAR-T/SILK (CD19-TriCAR-T/SILK)

Non-Hodgkin Lymphoma of Intestine; Leukemia · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 2상태 ACTIVE
CGTBiologicstaleShanghai Ming Ju Biotechnology …Phase 2

CD19-targeted Chimeric Antigen Receptor (CAR, CD19-targeted Chimeric Antigen Receptor, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells)

Lymphoma, Non-Hodgkin; Diffuse Large B Cell Lymphoma · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+5
효능 ORR 94%임상시험 2상태 ACTIVE
CGTBiologicstaleEssen BiotechPhase 2

CD19/BCMA CAR T-cells (CD19/BCMA CAR T-cells)

Systemic Lupus Erythematosus; Lupus Nephritis · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 2상태 RECRUITING
CGTBiologicstaleHan weidongPhase 2

Decitabine-primed Tandem CAR19/20 engineered T cells (Decitabine-primed Tandem CAR19/20 engineered T cells)

Refractory or Relapsed Aggressive r/r B-NHL With Huge Tumor Burden · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 2상태 RECRUITING
CGTBiologicstaleNanjing Legend Biotech Co.Phase 2

Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy (Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy)

Lymphoma, B-Cell · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 2상태 ACTIVE

3 / 11 페이지

← 이전다음 →